Friday, May 16, 2025

Why we recalled batch of Deekins Amoxycillin capsule — NAFDAC

Must read

Ibrahim Ramalan
Ibrahim Ramalan
Ibrahim Ramalan is a graduate of Mass Communications from the Ahmadu Bello University (ABU) Zaria. With nearly a decade-long, active journalism practice, Mr Ramalan has been able to rise from a cub reporter to the exalted position of an editor; first as Arts Editor with the Blueprint Newspapers before resigning in 2019; second and presently as an Associate Editor of the Daily Nigerian online newspaper. He can be reached via ibroramalan@gmail.com, or www.facebook.com/ibrahim.ramalana, or @McRamalan on Twitter.
- Advertisement -
tiamin rice
tiamin rice

The National Agency for Food and Drug Administration and Control, NAFDAC, has explained why it recalled one batch of Deekins Amoxycillin 500mg capsules.

This was made known in a statement on the Agency’s X (formerly Twitter) on Wednesday.

The affected batch, with lot number 4C639001, was manufactured by Eco-med Pharma Ltd and marketed by DevineKings Pharmaceutical Ltd.

tiamin rice

The agency said the recall followed reports of serious adverse drug reactions associated with this batch.

The statement said, “NAFDAC is notifying the public of the recall of one batch of Deekins Amoxycillin 500mg Capsules, manufactured by Eco-med Pharma Ltd and marketed by DevineKings Pharmaceutical Ltd, with lot number 4C639001.

whatsApp

“This batch is recalled following reports of serious adverse drug reactions.

“According to Eco-med Pharma Ltd, reports of serious adverse drug reactions were received from a hospital that reported three cases of serious adverse drug reactions from patients administered with the batch of Deekins Amoxycillin 500mg capsule.

“Amoxicillin is a penicillin antibiotic indicated for treating bacterial infections such as tonsillitis, bronchitis, sinusitis, pneumonia, and bacterial infections of the ear, nose, throat, skin, or urinary tract.”

According to Eco-med Pharma Ltd, a hospital reported three cases of severe reactions in patients who were administered capsules from this batch.

NAFDAC also advised healthcare professionals and consumers to immediately stop using the affected batch and to report any suspicious cases of substandard or falsified medicines to the nearest NAFDAC office.

“Healthcare professionals and consumers are advised to report any suspicion of substandard and falsified medicines to the nearest NAFDAC office, call 0800-162-3322 or send an email to sf.alert@nafdac.gov.ng.”

- Advertisement -

More articles

- Advertisement -

Latest article

- Advertisement -